Skip to content
10-Q/A

Quarterly Report

ALLOS THERAPEUTICS INC

0001104659-12-020833

← back to feed
Filed
Mar 26, 2012 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2011 · Nov 1, 2011 105.93M sh
Operating Cash Flow Q3 2011 · Sep 30, 2011 $1.76M
Operating Cash Flow Q3 2011 · Sep 30, 2010 −$52.92M
Cash And Equivalents Q3 2011 · Sep 30, 2011 $69.64M
Cash And Equivalents Q3 2011 · Dec 31, 2010 $48.16M
Cash And Equivalents Q3 2011 · Sep 30, 2010 $63.43M
Cash And Equivalents Q3 2011 · Dec 31, 2009 $141.19M
Stockholders Equity restated Q3 2011 · Sep 30, 2011 $78.65M
Stockholders Equity Q3 2011 · Dec 31, 2010 $98.2M
Current Liabilities restated Q3 2011 · Sep 30, 2011 $25.81M
Current Liabilities Q3 2011 · Dec 31, 2010 $22.56M
Current Assets Q3 2011 · Sep 30, 2011 $119.75M
Current Assets Q3 2011 · Dec 31, 2010 $113.17M
Total Assets Q3 2011 · Sep 30, 2011 $126.34M
Total Assets Q3 2011 · Dec 31, 2010 $120.76M
Sga Expense Q3 2011 · Sep 30, 2011 $18.69M
Sga Expense Q3 2011 · Sep 30, 2011 $56.4M
Sga Expense Q3 2011 · Sep 30, 2010 $18.7M
Sga Expense Q3 2011 · Sep 30, 2010 $57.15M
Net Income restated Q3 2011 · Sep 30, 2011 −$11.39M
Net Income restated Q3 2011 · Sep 30, 2011 −$29.1M
Net Income Q3 2011 · Sep 30, 2010 −$18.77M
Net Income Q3 2011 · Sep 30, 2010 −$59.28M
Operating Income restated Q3 2011 · Sep 30, 2011 −$11.41M
Operating Income restated Q3 2011 · Sep 30, 2011 −$29.19M
Operating Income Q3 2011 · Sep 30, 2010 −$18.72M
Operating Income Q3 2011 · Sep 30, 2010 −$59.36M
Revenue restated Q3 2011 · Sep 30, 2011 $14.06M
Revenue restated Q3 2011 · Sep 30, 2011 $59.35M
Revenue Q3 2011 · Sep 30, 2010 $8.23M
Revenue Q3 2011 · Sep 30, 2010 $23.52M